Entero Therapeutics, Inc.
ENTO
$0.544
$0.059712.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -37.10% | -24.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.75% | -36.41% | |||
| Operating Income | 31.75% | 36.41% | |||
| Income Before Tax | 20.60% | 37.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 91.96% | -522.52% | |||
| Earnings from Discontinued Operations | 29.12% | 35.90% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 89.71% | -374.17% | |||
| EBIT | 31.75% | 36.41% | |||
| EBITDA | 33.94% | 34.55% | |||
| EPS Basic | 91.30% | -452.12% | |||
| Normalized Basic EPS | -141.45% | 215.33% | |||
| EPS Diluted | 89.80% | -452.12% | |||
| Normalized Diluted EPS | -141.45% | 215.33% | |||
| Average Basic Shares Outstanding | 38.72% | -24.54% | |||
| Average Diluted Shares Outstanding | 38.72% | -24.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||